Nanoscope MOGENRY BLA Accepted for Retinitis Pigmentosa

The FDA has accepted and filed Nanoscope Therapeutics’ biologics license application (BLA) for MOGENRY (sonpiretigene isteparvovec, MCO-010), an optogenetic gene therapy for retinitis pigmentosa (RP) with severe vision loss. The privately held company announced the acceptance September 9. No target action date was disclosed, but the therapy’s Fast Track designation makes it eligible for priority review.

MOGENRY is built to be mutation-agnostic. Instead of repairing a specific faulty gene, it delivers a synthetic multi-characteristic opsin to retinal bipolar cells using an adeno-associated virus (AAV) vector, in a one-time, in-office intravitreal injection that makes the surviving inner retinal neurons directly light-sensitive and bypasses the lost photoreceptors. RP is caused by more than 1,000 mutations across over 100 genes and causes progressive loss of night and peripheral vision, with many patients legally blind by age 40. That is why Luxturna (voretigene neparvovec), the only approved ocular gene therapy, reaches just the narrow slice of patients with biallelic RPE65 mutations, and only after subretinal surgery and confirmatory genetic testing.

The BLA is supported by the RESTORE Phase 2b/3 trial (NCT04945772), a randomized, double-masked, sham-controlled study, and the first randomized controlled trial to show statistically significant visual acuity improvement in RP patients. Treated patients maintained an average best-corrected visual acuity gain of about 0.3 LogMAR, roughly three lines or 15 letters on a standard eye chart, with the effect sustained through three years in the REMAIN extension. The high-dose group improved 0.337 LogMAR versus sham at week 52 (p=0.0209). Treatment was well tolerated, with no treatment-related serious adverse events.

Because Nanoscope is private, there is no ticker or stock price to track. The financial relevance is the market: RP affects roughly one in 4,000 people, or about 100,000 people in the US, and a gene-agnostic therapy would reach essentially all of them rather than a single mutation. Orphan Drug and Fast Track designations carry seven-year exclusivity and an expedited review. Nanoscope’s MCO platform is also in development for Stargardt disease and geographic atrophy. The company has also secured Japan’s Sakigake and Orphan Drug designations across inherited retinal diseases, a first for a retinal gene therapy.

The catch is that a BLA acceptance is a step, not a verdict. The FDA has not yet set a PDUFA date, and advanced RP has historically produced little controlled evidence of visual improvement, so the agency will scrutinize the sham-controlled data closely.

What to watch next: the FDA’s decision timeline, which is not yet public. For how gene-therapy economics shape these launches, read the explainer on gene therapy pricing.

Source: Nanoscope Therapeutics BLA acceptance press release · RESTORE trial on ClinicalTrials.gov (NCT04945772)

What It Means for the Trade

There is no ticker to buy here — the trade is read-through and precedent. For ocular gene therapy, a filed BLA with randomized, sham-controlled data is scarce currency: RESTORE was the first controlled trial to show statistically significant visual-acuity gains in RP, which raises the evidentiary bar for everyone else in inherited retinal disease. If MOGENRY clears review, the approval legitimizes the optogenetic category — light-sensing machinery installed downstream of whatever mutation killed the photoreceptors — as a platform, and that is exactly what Nanoscope’s Stargardt and geographic atrophy programs are betting on.

The market math explains why this matters despite the private status. RP affects roughly one in 4,000 people — about 100,000 in the US — and because MOGENRY is mutation-agnostic, the addressable population is the entire disease rather than the slice Luxturna’s RPE65 genetic test gates. An office-based intravitreal injection also removes Luxturna’s two biggest bottlenecks: subretinal surgery and confirmatory genetic testing.

Mechanism and Trial Context

Optogenetics inverts standard gene-therapy logic. Instead of repairing a broken gene, MOGENRY installs a synthetic multi-characteristic opsin in surviving bipolar cells via AAV, making the inner retina itself light-sensitive — a bypass rather than a repair, which is why one construct can cover a disease driven by more than 1,000 mutations across 100-plus genes. The RESTORE dataset the FDA will interrogate: roughly a 0.3 LogMAR gain — about three lines — sustained through three years in the REMAIN extension, the high-dose group up 0.337 LogMAR versus sham at week 52, and zero treatment-related serious adverse events.

Risks and What Could Go Wrong

1. No PDUFA date has been set — Fast Track makes priority review possible, not guaranteed, and the timeline stays opaque until the FDA stamps one.
2. Visual-acuity endpoints in advanced RP are noisy, and regulators have almost no controlled-trial precedent here; the same novelty that makes the data landmark makes the review path uncharted.
3. One-time gene-therapy pricing is under siege — even a flawless approval lands in a reimbursement environment hostile to seven-figure curative price tags.
4. As a private company, Nanoscope’s manufacturing scale and launch capacity are unannounced unknowns — approval is only half the commercial question.